Spero Therapeutics has signed a licensing deal with Innovent Biologics for a monoclonal antibody targeting CD40L, called SP001. Spero will pay $35 million upfront and up to $1.05 billion in milestones, plus tiered royalties. Spero gets exclusive rights to develop and commercialize the drug worldwide except for mainland China, Taiwan, Hong Kong, and Macau, which Innovent retains. Spero is required to file an IND in the U.S. within 12 months and use commercially reasonable efforts to launch in at least one U.S. indication and one of several European or Japanese markets.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding SPERO THERAPEUTICS INC (SPRO)?

Major stakeholders currently include GSK plc ($21.5M), Pfizer Inc ($5.5M), Vanguard Capital Management LLC ($4.2M). Based on the latest 13F filings, there are a total of 50 tracked investment funds and institutions maintaining positions in SPRO.

What is the overall institutional sentiment toward SPRO recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $769.1K, driven by 17 managers accumulating shares while 23 reduced their exposure.

Which institutions have been selling or reducing their SPRO positions?

In the latest period, 11 funds trimmed their holdings, and 12 managers completely exited their positions. The aggregate reported sell value was $11.1M.

Are there any notable investors adding SPRO to their portfolios?

Yes, buying activity remains notable. 5 institutions opened new positions in {ticker}, and 12 existing holders added to their shares. The total reported buy value for the quarter amounted to $5.7M.